p40 (BC28)
Mouse Monoclonal Primary Antibody

p40 (BC28) is a ready-to-use IHC antibody that enables you to evaluate the expression of p40 (ΔNp63) protein with clinical confidence using the OptiView DAB IHC Detection Kit
p40 (BC28) is shown to be **as sensitive** as p63 (4A4) in non-small cell lung cancer but **more specific**. The use of p40 is recommended as a replacement for p63 when subclassifying non-small cell lung cancer to avoid falsely classifying p63+ adenocarcinoma as squamous cell carcinoma.²

![Squamous cell carcinoma stained positive with the p40 (BC28) assay using OptiView DAB IHC detection](image1)

![Squamous cell carcinoma stained positive with the p63 (4A4) assay using ultraView DAB IHC detection](image2)

![Adenocarcinoma stained negative with the p40 (BC28) assay using OptiView DAB IHC detection](image3)

![Adenocarcinoma stained positive with the p63 (4A4) assay using ultraView DAB IHC detection](image4)

**p40 (BC28) Antibody**

p40 (BC28) is a sensitive and specific antibody for the detection of the p40 (ΔNp63) protein. In a panel with other key markers in our portfolio (TTF-1, CK 5/6, Napsin A), p40 (BC28) can provide an accurate and reliable method for differentiating pulmonary adenocarcinoma from squamous cell carcinoma.³

The p40 (BC28) antibody can provide:

<table>
<thead>
<tr>
<th>High Sensitivity</th>
<th>p40 has been shown to be as sensitive as, if not more sensitive, than p63.²,¹³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Higher Specificity</td>
<td>Multiple studies indicate that p40 has higher specificity in pulmonary squamous cell carcinomas compared to p63.²⁻¹¹</td>
</tr>
<tr>
<td>Suitable Replacement</td>
<td>p40 may offer a suitable replacement for p63 in various tumor types beyond lung (bladder, prostate, breast and head and neck cancers).³⁻¹⁶</td>
</tr>
<tr>
<td>Key Marker</td>
<td>p40 (BC28) can serve in a panel of other key markers (TTF-1, Napsin A, CK 5/6) to aid in the accurate distinction between adenocarcinomas and squamous cell carcinomas of the lung.³</td>
</tr>
<tr>
<td>Consistent Performance</td>
<td>p40 (BC28) is a pre-diluted, ready-to-use assay optimized for use on the BenchMark IHC/ISH automated staining platforms which provides a workflow solution that may free up resources, lower labor costs and reduce time to results.</td>
</tr>
</tbody>
</table>

In non-small cell lung cancer but **more specific**. The use of p40 is recommended as a replacement for p63 when subclassifying non-small cell lung cancer to avoid falsely classifying p63+ adenocarcinoma as squamous cell carcinoma.²
<table>
<thead>
<tr>
<th>Product name</th>
<th>Catalog number</th>
<th>Ordering number</th>
<th>Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>p40 (BC28) Mouse Monoclonal Primary Antibody</td>
<td>790-4950</td>
<td>07394420001</td>
<td>50</td>
</tr>
</tbody>
</table>

**References**


7. Tacha, David PhD; Ryan Bremer, PhD; Thomas Haas, DO; Weiman Qi, PhD, MD. An Immunohistochemical Analysis of a Newly Developed, Mouse Monoclonal p40 (BC28) Antibody in Lung, Bladder, Skin, Breast, Prostate and Head and Neck Cancers. Arch Pathol Lab Med—Vol 138, October 2014.


14. Rooper, Lisa, Rajni Sharma, Justin A. Bishop. Polymorphous Low Grade Adenocarcinoma has a Consistent p63+/p40–Immunophenotype that Helps Distinguish it from Adenoid Cystic Carcinoma and Cellular Pleomorphic Adenoma. Head and Neck Pathol. 2014. DOI 10.1007/s12105-014-0554-4-4